Floatz logo

Selpercatinib

Other Solid Tumors With Evidence of Activating RET Alteration

Small moleculeDormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

8 Active assets in the Other Solid Tumors With Evidence of Activating RET Alteration cohort.

Asset / SponsorPhaseRating
Regorafenib
University of California, San Francisco
Phase 2CCC
Ceritinib
University of California, San Francisco
Phase 2CCC
Carboplatin
Guangdong Provincial People's Hospital
Phase 2CCC
Entrectinib
University of California, San Francisco
Phase 2CCC
Toripalimab
Guangdong Provincial People's Hospital
Phase 2CCC

View all 14 →

Same molecule, other indications

Selpercatinib is also rated in:

medullary thyroid gland carcinomaDormant
B
Indicative ·
60 / 100
View asset →
soft tissue sarcomaDormant
B
Indicative ·
60 / 100
View asset →
non-small cell lung carcinomaDormant
B
Indicative ·
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →